Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Donepezil.

P J Whitehouse¹

¹Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio 44120-1013, USA.

Drugs of Today (Barcelona, Spain : 1998)

|March 11, 2004

Summary

This summary is machine-generated.

Donepezil, an acetylcholinesterase inhibitor, improves cognitive function and daily living in Alzheimer's disease patients. Further research is needed to confirm its long-term effects on dementia progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ethical issues in dementia.

Dialogues in clinical neuroscience·2011

Same author

The role of nutrients in the prevention and treatment of Alzheimer's disease: methodology for a systematic review.

European journal of neurology·2009

Same author

Speaking of research advance directives: planning for future research participation.

Neurology·2006

Same author

Twenty-four-hour rhythms of sleep-wake cycle and temperature in Alzheimer's disease.

The Journal of neuropsychiatry and clinical neurosciences·2004

Same author

Paying attention to acetylcholine: the key to wisdom and quality of life?

Progress in brain research·2003

Same author

Vinpocetine for cognitive impairment and dementia.

The Cochrane database of systematic reviews·2003

Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

See all related articles

Area of Science:

Neuroscience
Pharmacology
Geriatrics

Background:

Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline.
Acetylcholine deficiency in the brain is a key feature of Alzheimer's disease pathology.
Donepezil is an acetylcholinesterase inhibitor developed for Alzheimer's treatment.

Purpose of the Study:

To evaluate the efficacy of donepezil in treating Alzheimer's disease.
To assess the impact of donepezil on cognitive function and patient performance.
To determine the long-term effects of donepezil on Alzheimer's disease and related dementias.

Main Methods:

Conducted large-scale, multinational clinical studies.
Utilized objective psychometric tests to measure cognitive performance.

Related Experiment Videos

Employed clinician ratings to assess patient function.

Main Results:

Donepezil demonstrated significant drug-related improvements in cognitive performance.
Clinical studies showed enhanced patient function as rated by clinicians.
The drug is approved in numerous countries for Alzheimer's treatment.

Conclusions:

Donepezil effectively improves cognitive function in Alzheimer's disease patients.
The drug shows promise in correcting acetylcholine dysfunction.
Long-term impact and efficacy require further investigation.